General Archive
-
News releasesNew £4.25 million grant kick starts UK-wide collaborative research effort to end motor neuron disease
Collaboration will work together to find solutions to MND within years, not decades
-
News releasesNew £30 million translational partnership will accelerate development of new treatments for people with dementia
Funding will accelerate development of new diagnostic tests, treatments, and devices for people with dementia.
-
News releasesPromising new asthma medicine ready to enter early clinical trials
LifeArc scientists instrumental to the development of the world’s first anti-IL17BR antibody, now being trialled as a treatment for severe…
-
News releasesPandemic Science Hub to develop better drugs to fight lung disease
New, multi-million pound research programme at the University of Edinburgh will develop treatments for lung infections
-
News releasesAction Medical Research and LifeArc announce a fourth round of funding to support translational research into children’s rare diseases
£1m fund to progress promising translational research addressing a medical need for children and young people
-
News releasesLifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2
LONDON, UK, 17 May 2022 — LifeArc today announced that RQ Biotechnology Ltd (RQ Bio), a company it co-founded, has…
-
News releasesLifeArc and Scottish Government work together to drive Scottish research into rare diseases
LifeArc and the Chief Scientist Office (CSO) for the Scottish Government have today jointly awarded a total of £300,000 to…
-
News releasesStudy reveals gene faults underpinning severe COVID-19
The study paves the way for new tests and treatments to protect people from infection.
-
News releasesLifeArc elects new Board Chair to drive charity’s ambitious strategy
Dr Ian Gilham appointed new Chair of Trustees to succeed Dr John Stageman when he steps down on 4 April…
-
News releasesNew study explores unique approach to treat a rare liver disease
A research study looking into a new approach to treat primary sclerosing cholangitis (PSC) is progressing to clinical trials.
-
News releasesLifeArc bolsters scientific leadership by appointing new Chief Scientific Officer
Welcome to Dr Dave Powell, who has joined LifeArc as our first Chief Scientific Officer (CSO). Dave is an experienced scientist and leader, with exceptional translational…
-
News releasesLifeArc participates in Series A funding round for company developing pioneering new gene therapies for neurodegenerative diseases
Helping to progress an innovative gene therapy platform from the bench to a stage where it is progressing closer to…